Covering Basic Needs on Molecular Imaging

Movement Disorders Clinical PracticeEarly View VIEWPOINT Covering Basic Needs on Molecular Imaging Cecilia Peralta MD, Cecilia Peralta MD orcid.org/0009-0002-5879-2488 Movement Disorders Clinic, Neuroscience Department, Hospital Universitario CEMIC, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, Buenos Aires, ArgentinaSearch for more papers by this authorAntonio P. Strafella MD, PhD, Antonio P. Strafella MD, PhD orcid.org/0000-0002-7779-0974 Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Division of Neurology/Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, ON, CanadaSearch for more papers by this authorHan-Joon Kim MD, PhD, Corresponding Author Han-Joon Kim MD, PhD [email protected] orcid.org/0000-0001-8219-9663 Department of Neurology and Movement Disorder Center, Seoul National University Hospital, Seoul, Korea Correspondence to: Han-Joon Kim, MD, PhD, Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, Republic of Korea; E-mail: [email protected]Search for more papers by this author Cecilia Peralta MD, Cecilia Peralta MD orcid.org/0009-0002-5879-2488 Movement Disorders Clinic, Neuroscience Department, Hospital Universitario CEMIC, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, Buenos Aires, ArgentinaSearch for more papers by this authorAntonio P. Strafella MD, PhD, Antonio P. Strafella MD, PhD orcid.org/0000-0002-7779-0974 Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Division of Neurology/Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, ON, CanadaSearch for more papers by this authorHan-Joon Kim MD, PhD, Corresponding Author Han-Joon Kim MD, PhD [email protected] orcid.org/0000-0001-8219-9663 Department of Neurology and Movement Disorder Center, Seoul National University Hospital, Seoul, Korea Correspondence to: Han-Joon Kim, MD, PhD, Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, Republic of Korea; E-mail: [email protected]Search for more papers by this author First published: 19 October 2023 https://doi.org/10.1002/mdc3.13905Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 NUMDAB, NUclear Medicine DAtaBase; https://humanhealth.iaea.org/HHW/NuclearMedicine/NUMDAB/index.html. 2 IMAGINE, the new IAEA Medical imaging and Nuclear medicine global resources database; https://humanhealth.iaea.org/HHW/DBStatistics/IMAGINE.html. 3Peralta C, Strafella AP, van Eimeren T, et al. Pragmatic approach on neuroimaging techniques for the differential diagnosis of Parkinsonisms. Mov Disord Clin Pract 2022; 9: 6–19. 4Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30: 1591–1601. 5Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–676. 6McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017; 89: 88–100. 7Paez D, Giammarile F, Orellana P. Nuclear medicine: a global perspective. Clin Transl Imaging 2020; 8: 51–53. 8Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998; 39: 1500–1508. 9Tatsch K, Schwarz J, Mozley PD, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123 I] IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24: 415–421. 10Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther 2008; 14: 47–64. 11Huang W-S, Chiang Y-H, Lin J-C, Chou Y-H, Cheng C-Y, Liu R-S. Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients. J Nucl Med 2003; 44: 999–1005. 12Arena JE, Urrutia L, Falasco G, Leon MP, Vazquez S, Rossi M, Merello M. Correlation between 99m Tc-TRODAT-1 SPECT and 18 F-FDOPA PET in patients with Parkinson's disease: a pilot study. Radiol Bras 2021; 54: 232–237. 13Kaasinen V, Vahlberg T. Striatal dopamine in P arkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017; 82: 873–882. 14Nahmias C, Garnett S, Firnau G, Lang A. Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 1985; 69(3): 223–230. 15https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf. 16Darcourt J, Schiazza A, Sapin N, et al. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. QJ Nucl Med Mol Imaging 2014; 58: 355–365. 17Lin S-C, Lin K-J, Hsiao T, et al. In vivo detection of monoaminergic degeneration in early Parkinson disease by 18F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J Nucl Med 2014; 55: 73–79. 18Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 2013; 36: 587–597. 19Holtbernd F, Ma Y, Peng S, et al. Dopaminergic correlates of metabolic network activity in Parkinson's disease. Hum Brain Mapp 2015; 36: 3575–3585. 20Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, Eidelberg D. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912–921. 21Ishibashi K, Saito Y, Murayama S, et al. Validation of cardiac 123 I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 2010; 37: 3–11. 22Frija G, Blažić I, Frush DP, Hierath M, Kawooya M, Donoso-Bach L, Brkljačić B. How to improve access to medical imaging in low-and middle-income countries? EClinicalMedicine 2021; 38:101034. 23Wu P, Zhao Y, Wu J. Differential diagnosis of parkinsonism based on deep metabolic imaging indices. Eur J Nucl Med Mol Imaging 2022; 49(8): 2798–2811. 24Landolfi A, Ricciardi C, Donisi L, et al. Machine learning approaches in Parkinson's disease. Curr Med Chem 2021; 28(32): 6548–6568. Early ViewOnline Version of Record before inclusion in an issue This article also appears in:MDCP Conference on Disparities and Inequities in the Availability of Therapies and Diagnostic Procedures Across Regions of the World - Kolkata, 2023 ReferencesRelatedInformation